Literature DB >> 23829357

Application of the docking program SOL for CSAR benchmark.

Alexey V Sulimov1, Danil C Kutov, Igor V Oferkin, Ekaterina V Katkova, Vladimir B Sulimov.   

Abstract

This paper is devoted to results obtained by the docking program SOL and the post-processing program DISCORE at the CSAR benchmark. SOL and DISCORE programs are described. SOL is the original docking program developed on the basis of the genetic algorithm, MMFF94 force field, rigid protein, precalculated energy grid including desolvation in the frame of simplified GB model, vdW, and electrostatic interactions and taking into account the ligand internal strain energy. An important SOL feature is the single- or multi-processor performance for up to hundreds of CPUs. DISCORE improves the binding energy scoring by the local energy optimization of the ligand docked pose and a simple linear regression on the base of available experimental data. The docking program SOL has demonstrated a good ability for correct ligand positioning in the active sites of the tested proteins in most cases of CSAR exercises. SOL and DISCORE have not demonstrated very exciting results on the protein-ligand binding free energy estimation. Nevertheless, for some target proteins, SOL and DISCORE were among the first in prediction of inhibition activity. Ways to improve SOL and DISCORE are discussed.

Mesh:

Substances:

Year:  2013        PMID: 23829357     DOI: 10.1021/ci400094h

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  11 in total

1.  Accuracy comparison of several common implicit solvent models and their implementations in the context of protein-ligand binding.

Authors:  E V Katkova; A V Onufriev; B Aguilar; V B Sulimov
Journal:  J Mol Graph Model       Date:  2016-12-21       Impact factor: 2.518

2.  New Blood Coagulation Factor XIIa Inhibitors: Molecular Modeling, Synthesis, and Experimental Confirmation.

Authors:  Anna Tashchilova; Nadezhda Podoplelova; Alexey Sulimov; Danil Kutov; Ivan Ilin; Mikhail Panteleev; Khidmet Shikhaliev; Svetlana Medvedeva; Nadezhda Novichikhina; Andrey Potapov; Vladimir Sulimov
Journal:  Molecules       Date:  2022-02-12       Impact factor: 4.411

3.  Novel Inhibitors of 2'-O-Methyltransferase of the SARS-CoV-2 Coronavirus.

Authors:  Alexey Sulimov; Danil Kutov; Ivan Ilin; Yibei Xiao; Sheng Jiang; Vladimir Sulimov
Journal:  Molecules       Date:  2022-04-23       Impact factor: 4.927

4.  CSAR 2014: A Benchmark Exercise Using Unpublished Data from Pharma.

Authors:  Heather A Carlson; Richard D Smith; Kelly L Damm-Ganamet; Jeanne A Stuckey; Aqeel Ahmed; Maire A Convery; Donald O Somers; Michael Kranz; Patricia A Elkins; Guanglei Cui; Catherine E Peishoff; Millard H Lambert; James B Dunbar
Journal:  J Chem Inf Model       Date:  2016-05-17       Impact factor: 4.956

5.  Application of Molecular Modeling to Development of New Factor Xa Inhibitors.

Authors:  Vladimir B Sulimov; Irina V Gribkova; Maria P Kochugaeva; Ekaterina V Katkova; Alexey V Sulimov; Danil C Kutov; Khidmet S Shikhaliev; Svetlana M Medvedeva; Michael Yu Krysin; Elena I Sinauridze; Fazoil I Ataullakhanov
Journal:  Biomed Res Int       Date:  2015-09-21       Impact factor: 3.411

6.  Evaluation of Docking Target Functions by the Comprehensive Investigation of Protein-Ligand Energy Minima.

Authors:  Igor V Oferkin; Ekaterina V Katkova; Alexey V Sulimov; Danil C Kutov; Sergey I Sobolev; Vladimir V Voevodin; Vladimir B Sulimov
Journal:  Adv Bioinformatics       Date:  2015-11-26

7.  Combined Docking with Classical Force Field and Quantum Chemical Semiempirical Method PM7.

Authors:  A V Sulimov; D C Kutov; E V Katkova; V B Sulimov
Journal:  Adv Bioinformatics       Date:  2017-01-16

8.  Evaluation of the novel algorithm of flexible ligand docking with moveable target-protein atoms.

Authors:  Alexey V Sulimov; Dmitry A Zheltkov; Igor V Oferkin; Danil C Kutov; Ekaterina V Katkova; Eugene E Tyrtyshnikov; Vladimir B Sulimov
Journal:  Comput Struct Biotechnol J       Date:  2017-03-03       Impact factor: 7.271

9.  Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa.

Authors:  Nadezhda Novichikhina; Ivan Ilin; Anna Tashchilova; Alexey Sulimov; Danil Kutov; Irina Ledenyova; Mikhail Krysin; Khidmet Shikhaliev; Anna Gantseva; Ekaterina Gantseva; Nadezhda Podoplelova; Vladimir Sulimov
Journal:  Molecules       Date:  2020-04-19       Impact factor: 4.411

10.  Application of molecular modeling to urokinase inhibitors development.

Authors:  V B Sulimov; E V Katkova; I V Oferkin; A V Sulimov; A N Romanov; A I Roschin; I B Beloglazova; O S Plekhanova; V A Tkachuk; V A Sadovnichiy
Journal:  Biomed Res Int       Date:  2014-05-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.